US-based healthcare services provider McKesson has agreed to acquire Precision Medicine Group for $2.25 billion. The deal aims to bolster McKesson's clinical research and biopharmaceutical commercialisation services. Upon completion, Precision Medicine Group will operate under McKesson's oncology and multi-speciality segment, pending customary closing conditions and regulatory approvals.